Enlivex Therapeutics (ENLV) Competitors $1.19 +0.04 (+3.48%) Closing price 03/7/2025 04:00 PM EasternExtended Trading$1.38 +0.19 (+15.55%) As of 03/7/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends ENLV vs. HLVX, ADVM, SKYE, ANL, CRBP, ANRO, RANI, PLRX, IFRX, and JSPRShould you be buying Enlivex Therapeutics stock or one of its competitors? The main competitors of Enlivex Therapeutics include HilleVax (HLVX), Adverum Biotechnologies (ADVM), Skye Bioscience (SKYE), Adlai Nortye (ANL), Corbus Pharmaceuticals (CRBP), Alto Neuroscience (ANRO), Rani Therapeutics (RANI), Pliant Therapeutics (PLRX), InflaRx (IFRX), and Jasper Therapeutics (JSPR). These companies are all part of the "pharmaceutical products" industry. Enlivex Therapeutics vs. HilleVax Adverum Biotechnologies Skye Bioscience Adlai Nortye Corbus Pharmaceuticals Alto Neuroscience Rani Therapeutics Pliant Therapeutics InflaRx Jasper Therapeutics HilleVax (NASDAQ:HLVX) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, community ranking, earnings, valuation and profitability. Does the media prefer HLVX or ENLV? In the previous week, Enlivex Therapeutics had 9 more articles in the media than HilleVax. MarketBeat recorded 9 mentions for Enlivex Therapeutics and 0 mentions for HilleVax. Enlivex Therapeutics' average media sentiment score of 0.57 beat HilleVax's score of 0.00 indicating that Enlivex Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment HilleVax Neutral Enlivex Therapeutics Positive Do institutionals & insiders have more ownership in HLVX or ENLV? 86.4% of HilleVax shares are held by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are held by institutional investors. 71.1% of HilleVax shares are held by company insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has higher valuation and earnings, HLVX or ENLV? Enlivex Therapeutics is trading at a lower price-to-earnings ratio than HilleVax, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHilleVaxN/AN/A-$123.57M-$3.10-0.59Enlivex TherapeuticsN/AN/A-$29.07M-$0.98-1.21 Which has more volatility and risk, HLVX or ENLV? HilleVax has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Does the MarketBeat Community prefer HLVX or ENLV? Enlivex Therapeutics received 47 more outperform votes than HilleVax when rated by MarketBeat users. Likewise, 80.28% of users gave Enlivex Therapeutics an outperform vote while only 58.82% of users gave HilleVax an outperform vote. CompanyUnderperformOutperformHilleVaxOutperform Votes1058.82% Underperform Votes741.18% Enlivex TherapeuticsOutperform Votes5780.28% Underperform Votes1419.72% Do analysts rate HLVX or ENLV? HilleVax presently has a consensus price target of $3.00, suggesting a potential upside of 63.04%. Enlivex Therapeutics has a consensus price target of $9.50, suggesting a potential upside of 698.32%. Given Enlivex Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Enlivex Therapeutics is more favorable than HilleVax.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HilleVax 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Enlivex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Is HLVX or ENLV more profitable? HilleVax's return on equity of -67.27% beat Enlivex Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets HilleVaxN/A -67.27% -51.99% Enlivex Therapeutics N/A -67.57%-58.45% SummaryEnlivex Therapeutics beats HilleVax on 11 of the 16 factors compared between the two stocks. Remove Ads Get Enlivex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENLV vs. The Competition Export to ExcelMetricEnlivex TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.47M$7.31B$5.86B$8.33BDividend YieldN/A2.75%4.89%4.02%P/E Ratio-1.216.2925.1819.36Price / SalesN/A224.97378.11118.07Price / CashN/A65.6738.1234.62Price / Book0.736.517.304.23Net Income-$29.07M$140.25M$3.19B$247.13M7 Day Performance-0.83%-2.36%-1.61%-2.38%1 Month Performance8.18%-3.90%-3.73%-6.15%1 Year Performance-69.87%-10.34%13.02%2.83% Enlivex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENLVEnlivex Therapeutics3.3528 of 5 stars$1.19+3.5%$9.50+698.3%-69.9%$25.47MN/A-1.2170Short Interest ↓High Trading VolumeHLVXHilleVax2.2889 of 5 stars$1.75-2.2%$3.00+71.4%-90.0%$87.16MN/A-0.5620ADVMAdverum Biotechnologies3.9212 of 5 stars$4.16-11.7%$27.83+569.1%-75.6%$86.54M$1M-0.69190SKYESkye Bioscience0.9079 of 5 stars$2.51-8.2%$18.67+645.2%-80.3%$86.46MN/A0.0011Gap UpANLAdlai Nortye2.5677 of 5 stars$2.30+1.8%$9.00+291.3%-69.2%$84.87M$5M0.00127Short Interest ↓Positive NewsGap UpHigh Trading VolumeCRBPCorbus Pharmaceuticals3.7313 of 5 stars$6.96-7.8%$61.38+781.8%-84.9%$84.77MN/A-1.4840Upcoming EarningsAnalyst UpgradeANROAlto Neuroscience1.4525 of 5 stars$3.14+12.1%$16.75+433.4%-74.2%$84.69MN/A0.00N/AGap UpHigh Trading VolumeRANIRani Therapeutics3.3579 of 5 stars$1.47-3.9%$12.33+739.0%-58.8%$84.22MN/A-1.39110PLRXPliant Therapeutics4.7138 of 5 stars$1.38-59.9%$13.88+905.4%-89.6%$83.98M$1.58M-0.4190Earnings ReportAnalyst ForecastAnalyst RevisionHigh Trading VolumeIFRXInflaRx3.1167 of 5 stars$1.25-10.1%$8.00+540.0%-25.3%$83.92M$168,498.00-1.1660Analyst ForecastNews CoverageGap UpHigh Trading VolumeJSPRJasper Therapeutics2.9999 of 5 stars$5.58-5.9%$64.44+1,054.9%-80.5%$83.71MN/A-1.1820Analyst Revision Remove Ads Related Companies and Tools Related Companies HLVX Competitors ADVM Competitors SKYE Competitors ANL Competitors CRBP Competitors ANRO Competitors RANI Competitors PLRX Competitors IFRX Competitors JSPR Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ENLV) was last updated on 3/9/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enlivex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ENLV Stock Alerts